Canary’s First-in-class Dual RNAi Gene Silencing Offers a Novel Approach to Weight Loss and Metabolic Disease Management
Canary Cure, a biotechnology company focused on developing innovative RNAi therapies, today announced the results of a diet-induced-obesity (DIO) mouse study demonstrating the potential of its first-in-class dual siRNA therapy, CCT-217, to achieve significant weight loss and improve metabolic health.